The role of angiogenic factors in endometrial cancer

Przeglad Menopauzalny

Volumn 18, Issue 2, 2014, Pages 122-126

  Zyła, Monika Magdalena ^a   Kostrzewa, Marta ^a   Litwińska, Ewelina ^b   Szpakowski, Artur ^a   Wilczyński, Jacek Radosław ^a   Stetkiewicz, Tomasz ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b Instytutu Cendtrum Zdrowia Matki Polki w odzi   (Poland)

Author keywords

Angiogenesis; Endometrial cancer; Growth factors; Placental growth factor; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; GROWTH FACTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ENDOMETRIUM CANCER; FEMALE; HUMAN; LYMPHANGIOGENESIS; REVIEW;

EID: 84901435386     PISSN: 16438876     EISSN: 22990038     Source Type: Journal    
DOI: 10.5114/pm.2014.42714     Document Type: Review

References (59)

1. World Cancer Report. Steward BW, Kleihues P (eds.). IARC Press, Lyon 2003. Uterine cancer, pp. 217-219.
2. Gabryś MS. Epidemiologia i etiopatogeneza raka błony śluzowej trzonu macicy. In: Ginekologia onkologiczna. Tom 2. Markowska H (ed.). Urban & Partner, Wrocław 2006, pp. 683-685.
3. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide. IARC, Lyon 2008; http://globocan.iarc.fr/
4. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009; 16: 14-22.
5. Tumours of the uterine corpus. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA, Devilee P (eds.). IARC Press, Lyon 2003, pp. 217-257.
6. Urbański K, Kornafel J (eds.). Ginekologia onkologiczna. In: Zalecenia postȩpowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Media, Gdańsk 2007. Czȩś ć I. Onkologia w praktyce klinicznej 2007; 3 (suppl C): pp. 235-240.
7. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17. (Pubitemid 13194678)
8. Hanahan D, Folkamn J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364. (Pubitemid 26272076)
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
10. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
11. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50: 63-70. (Pubitemid 32166291)
12. Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040-1041. (Pubitemid 32717529)
13. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674. (Pubitemid 27193480)
14. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50. (Pubitemid 27450640)
15. Casper RF. Regulation of estrogen/progesterone receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41: 16-21.
16. Brooks PC, Strömblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
17. Skobe M, Rockwell P, Goldstein N, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-1227. (Pubitemid 27508822)
18. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
19. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003; 361: 1959.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
21. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684. (Pubitemid 36749216)
22. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
23. Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550-563. (Pubitemid 40138976)
24. Stuttfeld E, Ballmer-Hofer K. Structure and functionof VEGF receptors. IUBMB Life 2009; 61: 915-922.
25. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10. (Pubitemid 41680947)
26. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006; 96: 223-268.
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
28. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114 (Pt 5): 853-865. (Pubitemid 32273121)
29. Saharinen P, Tammela T, Karkkainen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25: 387-395. (Pubitemid 38780956)
30. Siegfried G, Basak A, Cromlish JA, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003; 111: 1723-1732. (Pubitemid 38057753)
31. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci 1991; 88: 9267-9271. (Pubitemid 21915612)
32. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8: 925-931. (Pubitemid 23087424)
33. Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placenta growth factor (PIGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 2003; 60: 53-60. (Pubitemid 37272295)
34. Autiero M, Waltenberger J, Communi D, et al. Role of PLGF in the intra- and intermolecular cross talk between the VEGF receptors Flt 1 and Flk 1. Nat Med 2003; 9: 936-943. (Pubitemid 36889938)
35. Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates collapsing-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsing-1 and vascular endothelial growth factor-165. J Cell Biol 1999; 146: 233-242.
36. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
37. Viita H, Markkanen J, Eriksson E, et al. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and down regulation of VEGF receptor 2 expression. Circ Res 2008; 102: 177-184. (Pubitemid 351651121)
38. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583. (Pubitemid 32448325)
39. Perscio MG, VincentiV, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PLGF). Curr Top Microbiol Immunol 1999; 237: 41-40.
40. Voros G, Maquoi E, Demeulemeester D, et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-4554. (Pubitemid 41324053)
41. Zhang L, Chen J, Ke Y, et al. Expression of placenta growth factor (PLGF) in non small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005; 3: 68.
42. Wei SC, Tsao PN, Yu SC, et al. Placentha growth factor is correlated with survival of patients with colorectal cancer. Gut 2005; 54: 666-672.
43. Matsumoto K, Suzuki K, Kolke H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003; 23: 4953-4958. (Pubitemid 38182110)
44. Wei SC, Liang JT, Tsao PN, et al. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009; 52: 1630-1636.
45. Parr C, Watkins G, Boulton M, et al. Placenta growth factor in over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005; 41: 2819-2827. (Pubitemid 41713119)
46. Heeschen C, Dimmeler C, Fichtlscherer S, et al. Prognostic value of placenta growth factor in patients with acute chest pain. JAMA 2004; 291: 435-441. (Pubitemid 38129747)
47. Lendrink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 307-311. (Pubitemid 43063247)
48. Kagawa S, Matsumoto A, Yagi Y, et al. The time-course analysis of gene expression during wound healing in mouse skin. Leg Med 2009; 11: 70-75.
49. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996; 271: 3154-3162. (Pubitemid 26060529)
50. Schromber T, Kopfstein I, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 2007; 67: 10840-10848. (Pubitemid 350145913)
51. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006; 66: 3971-3977.
52. Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1995; 78: 454-460.
53. Smith SK. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 1998; 4: 509-519. (Pubitemid 29041463)
54. Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999; 72: 220-231. (Pubitemid 29093779)
55. Zhang L, Scott PA, Turley H, et al. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the humanendometrium. J Pathol 1998; 185: 402-408. (Pubitemid 28355973)
56. Saito M, Sato Y, Watanabe J, et al. Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Pathol Int 2007; 50: 140-147. (Pubitemid 46239380)
57. Fujimoto J, Ichigo S, Hirose R, et al. Expression of vascular endothelial growth factor (VEGF) and it's mRNA inuterine endometrial cancers. Cancer Lett 1998; 134: 15-22. (Pubitemid 29070845)
58. Giatromanolaki A, Siviridis E, Brekken R, et al. The angiogenic "Vascular endothelial growth factor/flk-1 (KDR) receptor" pathway in patients with endometrial carcinoma. Cancer 2001; 92: 2569-2577. (Pubitemid 33049440)
59. Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep 2013; 29: 413-418.